This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Basciani, S. Articles by Gnessi, L. Search for Related Content PubMed PubMed Citation Articles by Basciani, S. Articles by Gnessi, L.

Imatinib Mesylate Inhibits Leydig Cell Tumor Growth: Evidence for In vitro and In vivo Activity

¹ Department of Medical Physiopathology, Policlinico Umberto I, University of Rome "La Sapienza", ² Department of Public Health and Cell Biology, Section of Anatomy, University of Rome "Tor Vergata", Rome; ³ Department of Oncology, Sigma-Tau Pharmaceutical Industries, Pomezia, Italy

Requests for reprints: Lucio Gnessi, Department of Medical Physiopathology, Policlinico Umberto I, University of Rome "La Sapienza", 00161 Rome, Italy. Phone: 39-6-4997-0509; Fax: 39-6-4461-450; E-mail: lucio.gnessi{at}uniroma1.it.

Leydig cell tumors are usually benign tumors of the male gonad. However, if the tumor is malignant, no effective treatments are currently available. Leydig cell tumors express platelet-derived growth factor (PDGF), kit ligand and their respective receptors, PDGFR and c-kit. We therefore evaluated the effects of imatinib mesylate (imatinib), a selective inhibitor of the c-kit and PDGFR tyrosine kinases, on the growth of rodent Leydig tumor cell lines in vivo and in vitro, and examined, in human Leydig cell tumor samples, the expression of activated PDGFR and c-kit and the mutations in exons of the c-kit gene commonly associated with solid tumors. Imatinib caused concentration-dependent decreases in the viability of Leydig tumor cell lines, which coincided with apoptosis and inhibition of proliferation and ligand-stimulated phosphorylation of c-kit and PDGFRs. Mice bearing s.c. allografts of a Leydig tumor cell line treated with imatinib p.o., had an almost complete inhibition of tumor growth, less tumor cell proliferation, increased apoptosis, and a lesser amount of tumor-associated mean vessel density compared with controls. No drug-resistant tumors appeared during imatinib treatment but tumors regrew after drug withdrawal. Human Leydig cell tumors showed an intense expression of the phosphorylated form of c-kit and a less intense expression of phosphorylated PDGFRs. No activating mutations in common regions of mutation of the c-kit gene were found. Our studies suggest that Leydig cell tumors might be a potential target for imatinib therapy.

Key Words: Leydig cell tumor • imatinib • Genitourinary cancers: other • Protein tyrosine kinases

This article has been cited by other articles:

				S. Basciani, G. De Luca, S. Dolci, M. Brama, M. Arizzi, S. Mariani, G. Rosano, G. Spera, and L. Gnessi Platelet-Derived Growth Factor Receptor {beta}-Subtype Regulates Proliferation and Migration of Gonocytes Endocrinology, December 1, 2008; 149(12): 6226 - 6235. [Abstract] [Full Text] [PDF]

				R. P. Rocconi, K. S. Matthews, K. J. Kimball, M. G. Conner, A. C. Baker, and M. N. Barnes Expression of C-kit and Platelet-Derived Growth Factor Receptors in Ovarian Granulosa Cell Tumors Reproductive Sciences, September 1, 2008; 15(7): 673 - 677. [Abstract] [PDF]

				W. Liu, M. R. Baer, M. J. Bowman, P. Pera, X. Zheng, J. Morgan, R. A. Pandey, and A. R. Oseroff The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2 Clin. Cancer Res., April 15, 2007; 13(8): 2463 - 2470. [Abstract] [Full Text] [PDF]

				M. Brama, S. Basciani, S. Cherubini, S. Mariani, S. Migliaccio, M. Arizzi, G. Rosano, G. Spera, and L. Gnessi Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment Endocr. Relat. Cancer, March 1, 2007; 14(1): 61 - 72. [Abstract] [Full Text] [PDF]